MedTrace Logo

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2026-02-02

No results posted yet for this study

Summary

Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.

Conditions

  • Methamphetamine-dependence

Interventions

DRUG

Ibudilast

Ibudilast capsules will be orally ingested twice daily for 6 weeks.

DRUG

Placebo Oral Tablet

Placebo capsules will be orally ingested twice daily for 6 weeks.

Sponsors & Collaborators

  • Portland VA Medical Center

    collaborator FED

  • Oregon Health and Science University

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Milky Kohno, PhD · VA Portland Health Care System, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2025-10-15
Completion
2025-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341078 on ClinicalTrials.gov